Inflammation and benign prostatic hyperplasia: Clinical implications

Current Urology Reports

Volumn 12, Issue 4, 2011, Pages 274-277

  Chughtai, Bilal ^a   Lee, Richard ^a   Te, Alexis ^a   Kaplan, Steven ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Benign prostatic hyperplasia; BPH; CD4; Chemokines; Chronic prostatitis; COX 2; Cyclooxygenase; Cytokines; Epithelial cells; IL 7; Inflammation; Interleukin 7; Interleukins; Nitric oxide; Permixon; prostate specific antigen; Prostatitis; Vitamin D; Vitamin D pathway

Indexed keywords

ANDROGEN; CELECOXIB; ELOCALCITOL; ESTROGEN; INTERLEUKIN 8; NITRIC OXIDE; PLACEBO; PROSTAGLANDIN SYNTHASE; PROSTATE SPECIFIC ANTIGEN; SABAL EXTRACT; SCAVENGER; VITAMIN D; VITAMIN D RECEPTOR;

ANTIGENICITY; ANTIINFLAMMATORY ACTIVITY; AUTOIMMUNE DISEASE; CLINICAL FEATURE; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DISEASE ASSOCIATION; DISEASE COURSE; DRUG EFFICACY; ENZYME ACTIVITY; GENE EXPRESSION REGULATION; HUMAN; INFLAMMATION; INFLAMMATORY INFILTRATE; LOWER URINARY TRACT SYMPTOM; OXIDATIVE STRESS; PATHOGENESIS; PROSTATE EPITHELIUM; PROSTATE HYPERTROPHY; PROSTATECTOMY; PROSTATITIS; PROTEIN EXPRESSION; REVIEW;

CHRONIC DISEASE; CYTOKINES; DISEASE PROGRESSION; HUMANS; MALE; OXIDATIVE STRESS; PROGNOSIS; PROSTATIC HYPERPLASIA; PROSTATITIS;

EID: 79960587096     PISSN: 15272737     EISSN: 15346285     Source Type: Journal    
DOI: 10.1007/s11934-011-0191-3     Document Type: Review

References (18)

1. KT McVary 2006 BPH: epidemiology and comorbidities Am J Manag Care 12 5 Suppl S122 8 16613526
2. CG Roehrborn 2008 BPH progression: concept and key learning from MTOPS, ALTESS, COMBAT, and ALF-ONE BJU Int 101 Suppl 3 17 21 18307681 10.1111/j.1464-410X.2008.07497.x (Pubitemid 351328802)
3. VC Mishra, et al. 2007 Does intraprostatic inflammation have a role in the pathogenesis and progression of benign prostatic hyperplasia? BJU Int 100 2 327 31 17617139 10.1111/j.1464-410X.2007.06910.x (Pubitemid 47036563)
4. JC Nickel 1994 Prostatic inflammation in benign prostatic hyperplasia - the third component? Can J Urol 1 1 1 4 12834558 1:STN:280: DC%2BD3szgs1yqsQ%3D%3D
5. JC Nickel 2008 Inflammation and benign prostatic hyperplasia Urol Clin North Am 35 1 109 15 18061029 10.1016/j.ucl.2007.09.012 vii (Pubitemid 350166524)
6. G Robert, et al. 2009 Inflammation in benign prostatic hyperplasia: a 282 patients' immunohistochemical analysis Prostate 69 16 1774 80 19670242 10.1002/pros.21027 This study demonstrated a correlation between inflammation and clinically important parameters in patients with significant LUTS caused by BPH.
7. ME McDowell, et al. 2009 A review of prostate-specific antigen screening prevalence and risk perceptions for first-degree relatives of men with prostate cancer Eur J Cancer Care (Engl) 18 6 545 55 10.1111/j.1365-2354.2008.01046.x 1:STN:280:DC%2BD1MjjtlWjtA%3D%3D
8. GE Steiner, et al. 2003 Expression and function of pro-inflammatory interleukin IL-17 and IL-17 receptor in normal, benign hyperplastic, and malignant prostate Prostate 56 3 171 82 12772186 10.1002/pros.10238 1:CAS:528:DC%2BD3sXntVWgu7w%3D (Pubitemid 36918167)
9. W Wang A Bergh JE Damber 2004 Chronic inflammation in benign prostate hyperplasia is associated with focal upregulation of cyclooxygenase-2, Bcl-2, and cell proliferation in the glandular epithelium Prostate 61 1 60 72 15287094 10.1002/pros.20061 1:CAS:528:DC%2BD2cXnvVCnsLY%3D (Pubitemid 39095695)
10. KG Naber W Weidner 2000 Chronic prostatitis-an infectious disease? J Antimicrob Chemother 46 2 157 61 10933636 10.1093/jac/46.2.157 1:CAS:528:DC%2BD3cXmtFCju7g%3D
11. LM Sugar 2006 Inflammation and prostate cancer Can J Urol 13 Suppl 1 46 7 16526982
12. F Di Silverio, et al. 2003 Distribution of inflammation, pre-malignant lesions, incidental carcinoma in histologically confirmed benign prostatic hyperplasia: a retrospective analysis Eur Urol 43 2 164 75 12565775 10.1016/S0302-2838(02)00548-1 (Pubitemid 36221971)
13. S Falahatkar, et al. 2008 Celecoxib for treatment of nocturia caused by benign prostatic hyperplasia: a prospective, randomized, double-blind, placebo-controlled study Urology 72 4 813 6 18692876 10.1016/j.urology.2008.04. 069 This study by demonstrated the possible role of anti-inflammatories in the progression of BPH. In addition, this trial showed a statistically significant decrease in nocturia in the celecoxib group.
14. G Penna, et al. 2009 The vitamin D receptor agonist elocalcitol inhibits IL-8-dependent benign prostatic hyperplasia stromal cell proliferation and inflammatory response by targeting the RhoA/Rho kinase and NF-kappaB pathways Prostate 69 5 480 93 19107880 10.1002/pros.20896 1:CAS:528:DC%2BD1MXkvVWltbo%3D The authors were able to elucidate a pathway that eventually may be useful to decrease inflammation in those with clinically significant BPH.
15. G Penna, et al. 2006 Treatment of experimental autoimmune prostatitis in nonobese diabetic mice by the vitamin D receptor agonist elocalcitol J Immunol 177 12 8504 11 17142748 1:CAS:528:DC%2BD28Xht1Kitr7I (Pubitemid 44895295)
16. R Vela Navarrete, et al. 2003 BPH and inflammation: pharmacological effects of Permixon on histological and molecular inflammatory markers. Results of a double blind pilot clinical assay Eur Urol 44 5 549 55 14572753 10.1016/S0302-2838(03)00368-3 1:STN:280:DC%2BD3svpsF2ltA%3D%3D (Pubitemid 37328630)
17. RB Nadler, et al. 1995 Effect of inflammation and benign prostatic hyperplasia on elevated serum prostate specific antigen levels J Urol 154 2 Pt 1 407 13 7541857 1:STN:280:DyaK2Mzjtlehuw%3D%3D
18. JC Nickel, et al. 2007 Examination of the relationship between symptoms of prostatitis and histological inflammation: baseline data from the REDUCE chemoprevention trial J Urol 178 3 Pt 1 896 900 17632164 10.1016/j.juro.2007.05. 041 discussion 900-1 (Pubitemid 47211075)